Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings Inc (RANI) is a clinical-stage biotherapeutics leader developing oral alternatives to injectable biologic medications through its patented RaniPill technology. This page provides investors and industry observers with timely updates on corporate milestones, clinical trial progress, and strategic initiatives shaping the future of non-invasive drug administration.
Access official press releases, financial disclosures, and third-party analysis covering RANI's advancements in transforming treatments for chronic diseases. Key updates include trial results for oral biologic formulations, intellectual property developments, partnership announcements with pharmaceutical collaborators, and quarterly performance reports.
Bookmark this page for streamlined tracking of RANI's progress in addressing critical challenges in drug delivery. Return regularly to monitor how the company's capsule-based technology could impact treatment adherence, patient comfort, and the broader $500B+ biologics market.
Rani Therapeutics reported positive topline results from a Phase 1 study for RT-111, an oral anti-Interleukin 12/23 antibody, and plans to initiate a Phase 2 clinical trial for RT-102 for osteoporosis treatment in 2024. The company's RaniPill HC is set for potential Phase 1 trials later in 2024. Financially, Rani Therapeutics had $39.6 million in cash, cash equivalents, and marketable securities as of March 31, 2024, with a decrease in research and development expenses compared to the previous year.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
